Filing Analysis
MacroGenics, Inc. filed an 8-K to announce its financial and operating results for the quarter ended June 30, 2026. The filing serves as a formal announcement of the quarterly earnings release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2026.
- Announcement date: August 13, 2026.
- The company released financial and operating results via press release (Exhibit 99.1).
MacroGenics, Inc. issued an 8-K to provide a clinical update regarding its ongoing Phase 1 study of MGC026 via a press release.
📋 Key Facts
- Date of report: July 23, 2026
- Subject matter: Clinical update on Phase 1 study of MGC026
- The filing incorporates a press release as Exhibit 99.1
MacroGenics, Inc. announced the resignation of Karen Ferrante, M.D. from its Board of Directors. The resignation is effective September 1, 2026, and is attributed to personal reasons.
🚩 Red Flags
- None identified; company explicitly states no disagreement exists regarding operations or policies.
📋 Key Facts
- Karen Ferrante, M.D. resigned from the Board of Directors on July 1, 2026.
- The resignation becomes effective on September 1, 2026.
- The departure is for personal reasons and not due to any disagreement with the Company's operations, policies, or practices.
MacroGenics, Inc. has completed the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC for $122.5 million. The transaction effectively divests the company's manufacturing infrastructure while retaining its core research assets.
🚩 Red Flags
- Divestiture of core infrastructure (manufacturing) may increase reliance on third-party providers for future clinical or commercial production.
📋 Key Facts
- Transaction closed on June 30, 2026.
- Total consideration: $122.5 million (before fees and expenses) paid by Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC.
- Assets sold include GMP manufacturing operations at Rockville, MD and warehouse operations in Frederick, MD.
- The company retains all research and related assets/operations.
- Purchaser assumed responsibility for the CDMO Operations.
MacroGenics, Inc. reported the voting results from its 2026 Annual Meeting of Stockholders held on May 19, 2026. Stockholders approved the election of Class I directors, ratified the appointment of Ernst & Young LLP as the independent auditor for fiscal year 2026, approved executive compensation on an advisory basis, and approved an amendment to the 2023 Equity Incentive Plan.
📋 Key Facts
- The Annual Meeting was held on May 19, 2026, with approximately 58% of outstanding shares represented (36,744,013 shares out of 63,560,068).
- Class I directors Scott Koenig, M.D., Ph.D., Federica O'Brien, and Eric Risser were elected.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year 2026 with 36,689,683 votes 'For'.
- An amendment to the MacroGenics, Inc. 2023 Equity Incentive Plan was approved to increase the number of shares of common stock available for issuance by 1,250,000 shares.
MacroGenics, Inc. announced its financial and operating results for the first quarter ended March 31, 2026. The disclosure was made via a press release attached as Exhibit 99.1 to the filing.
📋 Key Facts
- The filing reports financial results for the quarter ended March 31, 2026.
- The report was filed on May 13, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- The information in the filing is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
MacroGenics announced the sale of its GMP manufacturing operations and CDMO business to Bora Pharmaceuticals for $122.5 million in cash. The transaction includes a long-term manufacturing and supply agreement ensuring MacroGenics retains access to clinical production services.
📋 Key Facts
- MacroGenics to receive $122.5 million in cash at closing, subject to customary adjustments.
- Potential for an additional $5 million in post-closing payments based on milestones and services through 2028.
- Assets being sold include the manufacturing facility in Rockville, Maryland, and warehouse operations in Frederick, Maryland.
- MacroGenics will enter into a manufacturing and supply agreement with the purchaser to secure future clinical supply.
- The transaction is expected to close in the third quarter of 2026.
MacroGenics amended its royalty purchase agreement with Sagard Healthcare Partners, securing an additional $60 million cash payment in exchange for royalty rights to ZYNYZ (retifanlimab-dlwr). This brings the total aggregate purchase price to $130 million, with a revised repayment cap and a potential $20 million milestone based on 2026 sales performance.
📋 Key Facts
- Received an additional $60.0 million cash payment from Sagard on May 1, 2026.
- Total aggregate purchase price for ZYNYZ royalties increased from $70 million to $130 million.
- Royalty rights revert to MacroGenics once Sagard receives 1.70x of the aggregate price by September 30, 2032, or 2.0x thereafter.
- Eligible for a one-time milestone payment of up to $20.0 million based on ZYNYZ achieving specific 2026 net sales thresholds.
- MacroGenics retains other economic interests including future development, regulatory, and commercial milestones under its original agreement with Incyte Corporation.
MacroGenics announced that the U.S. FDA has removed the partial clinical hold on its Phase 2 LINNET study of lorigerlimab. This allows the company to resume full clinical development of the bispecific DART molecule for patients with gynecologic cancers.
📋 Key Facts
- The FDA removed the partial clinical hold on April 8, 2026.
- The affected study is the Phase 2 LINNET trial.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study focuses on patients with gynecologic cancers.
MacroGenics, Inc. announced its financial and operating results for the fiscal year ended December 31, 2025. The results were disclosed via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial and operating results for the year ended December 31, 2025.
- The announcement was made on March 9, 2026.
- The information was furnished under Item 2.02 (Results of Operations and Financial Condition).
- A full press release is attached as Exhibit 99.1.
MacroGenics, Inc. announced that Class I director Jay Siegel, M.D. will not stand for re-election at the company's 2026 Annual Meeting of Stockholders. The departure is for personal reasons and does not involve any disagreements with the company.
📋 Key Facts
- Jay Siegel, M.D. notified the Board of Directors on February 25, 2026, that he will not seek re-election.
- Dr. Siegel is a Class I director.
- The decision was cited as being for personal reasons.
- The company stated there were no disagreements regarding operations, policies, or practices.
MacroGenics announced that the FDA has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in patients with gynecologic cancers.
🚩 Red Flags
- FDA partial clinical hold indicates potential safety concerns or regulatory deficiencies.
- Significant risk to clinical development timelines for a key pipeline asset.
📋 Key Facts
- The FDA issued a partial clinical hold on February 23, 2026.
- The affected study is the Phase 2 LINNET trial evaluating lorigerlimab.
- Lorigerlimab is an investigational bispecific DART molecule targeting PD-1 and CTLA-4.
- The study targets patients with gynecologic cancers.
MacroGenics, Inc. announced that Dr. Stephen Eck, Senior Vice President, Clinical Development and Chief Medical Officer, will depart the company effective December 31, 2025, via mutual agreement. Frank Perabo, M.D., Ph.D., will assume interim oversight of clinical development while a search for a permanent replacement is conducted.
🚩 Red Flags
- Loss of key executive leadership in the critical clinical development function during active study phases (implied by role).
📋 Key Facts
- Departure date: Effective December 31, 2025.
- Departing officer: Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development and Chief Medical Officer.
- Interim successor: Frank Perabo, M.D., Ph.D., Vice President, Clinical Development.
- Departure type: Mutual agreement; includes payments/benefits pursuant to a qualifying termination subject to a general release of claims.
MacroGenics, Inc. announced its financial and operating results for the quarter ended September 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025
- Announcement date: November 12, 2025
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial and operating results.
MacroGenics, Inc. announced its financial and operating results for the quarter ended June 30, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Quarter ended June 30, 2025
- The company released results via Exhibit 99.1 (Press Release)
- Trading symbol: MGNX (Nasdaq Global Select Market)
MacroGenics, Inc. has appointed Eric Risser, formerly the company's Chief Operating Officer, as the new President and Chief Executive Officer, effective August 13, 2025.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Eric Risser promoted from COO to President and CEO, effective August 13, 2025.
- Risser elected to the Board of Directors as a Class I director with a term expiring at the 2026 annual meeting.
- New compensation includes an annual base salary of $625,000 and eligibility for an annual incentive bonus of up to 60% of base salary.
- Risser was granted stock options to purchase 550,000 shares of common stock at the closing price on August 13, 2025.
- Severance terms include 1.0x salary + bonus for standard termination without cause, and 1.5x salary + bonus plus equity acceleration in a change-of-control scenario.
MacroGenics, Inc. entered into a Royalty Purchase Agreement with Sagard Healthcare Partners to sell its rights to future royalties from ZYNYZ (retifanlimab-dlwr) sales starting July 1, 2025. The company received an upfront cash payment of $70 million in exchange for these royalty rights.
🚩 Red Flags
- Monetization of future cash flows (royalties) can be a sign of limited liquidity or a need for immediate working capital to extend runway.
📋 Key Facts
- Company entered into a Royalty Purchase Agreement with Sagard Healthcare Partners on June 9, 2025.
- The agreement involves royalties from global net sales of ZYNYZ (retifanlimab-dlwr) under the Incyte Corporation License Agreement.
- MacroGenics received an immediate cash payment of $70.0 million.
- Sagard acquires royalties up to a cap of $140.0 million (2.0x the purchase price).
- After Sagard receives $140.0 million in aggregate royalty payments, MacroGenics resumes collecting all future royalties.
- MacroGenics retains other economic interests including development, regulatory, and commercial milestones.
MacroGenics, Inc. held its 2025 Annual Meeting of Stockholders on May 21, 2025. The meeting resulted in the successful election of four Class III directors and the approval of all other shareholder proposals, including auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting held on May 21, 2025.
- Quorum reached: 52,004,843 shares (approx. 82% of 63,090,323 outstanding shares).
- All four Class III director nominees (Karen Ferrante, William Heiden, Edward Hurwitz, and Meenu Chhabra Karson) were elected.
- Ratification of Ernst & Young LLP as independent auditor for fiscal year 2025 was approved.
- Advisory vote on named executive officer compensation was approved.
- Amendment to the 2023 Equity Incentive Plan to increase available shares by 1,250,000 was approved.
MacroGenics, Inc. announced its financial and operating results for the quarter ended March 31, 2025. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2025
- Announcement date: May 13, 2025
- The filing includes Exhibit 99.1 containing the full text of the press release regarding financial and operating results.
MacroGenics, Inc. announced its financial and operating results for the fiscal year ended December 31, 2024. The filing serves as a formal announcement of the company's year-end performance via an attached press release.
📋 Key Facts
- Reporting date: March 20, 2025
- Period covered: Fiscal year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) detailing financial and operating results.
MacroGenics has amended its separation agreement with CEO Dr. Scott Koenig, extending his departure date to a TBD date upon 14 days' notice and adjusting the duration of his advisory services. The company is currently in the process of searching for a successor.
🚩 Red Flags
- Uncertainty regarding the exact timing of the CEO's departure (requires 14 days' notice).
- Ongoing executive search for a new CEO, indicating leadership transition volatility.
📋 Key Facts
- Dr. Scott Koenig's original separation date was February 28, 2025.
- The Amendment extends the Separation Date to a date determined by the Board upon 14 days' notice to Dr. Koenig.
- Advisory services termination date extended from February 28, 2030, to five years after the new Separation Date.
- Dr. Koenig will receive a prorated target 2025 annual bonus following his separation.
MacroGenics, Inc. announced the retirement of Lynn Cilinski from her roles as VP, Controller, Treasurer, and Principal Accounting Officer, effective January 2, 2025. She will be succeeded by Beth Smith, an internal candidate who has been with the company since 2013.
🚩 Red Flags
- Departure of a long-tenured Principal Accounting Officer (PAO) can sometimes signal internal friction, though the retirement context and internal succession mitigate this risk.
📋 Key Facts
- Lynn Cilinski is retiring from her positions as VP, Controller, Treasurer, and Principal Accounting Officer on January 2, 2025.
- Beth Smith has been appointed to succeed Ms. Cilinski in the same roles, effective January 2, 2025.
- Ms. Cilinski has served the company for 21 years.
- Ms. Smith has been with MacroGenics since 2013 and most recently served as Executive Director of Accounting and Assistant Controller.
MacroGenics, Inc. announced its financial and operating results for the quarter ended September 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Report date: November 5, 2024
- Reporting period: Quarter ended September 30, 2024
- The company is listed on the Nasdaq Global Select Market (Ticker: MGNX)
- Financial results are detailed in Exhibit 99.1
MacroGenics Inc. announced the separation of its President and CEO, Dr. Scott Koenig, effective February 28, 2025. The company has formed a special executive search committee to identify a successor.
🚩 Red Flags
- Sudden departure of a President and CEO in a micro-cap biotech environment often signals internal transition or strategic shifts.
- Significant cash/benefit outflow via 24 months of salary continuation and COBRA premiums.
📋 Key Facts
- CEO Dr. Scott Koenig will separate from employment on February 28, 2025.
- Separation package includes 24 months of salary and target bonus continuation.
- Company will pay COBRA premiums for up to 24 months following the separation date.
- 50% of unvested stock options and RSUs will accelerate upon separation.
- Dr. Koenig will serve as an advisor from Feb 28, 2025, until Feb 28, 2030, to facilitate the vesting of remaining equity awards.
- A special executive search committee has been appointed by the Board to find a new CEO.
MacroGenics, Inc. issued an 8-K to announce updated efficacy and safety data from its Phase 2 TAMARACK clinical trial regarding vobramitamab duocarmazine for metastatic castration-resistant prostate cancer. The data was presented at the ESMO Congress in Barcelona.
📋 Key Facts
- Updated efficacy and safety data for Phase 2 TAMARACK clinical trial of vobramitamab duocarmazine released on September 15, 2024.
- Data presentation occurred at the European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain (Sept 13-17, 2024).
- The company held an investor conference call on September 16, 2024, to review trial data and provide a corporate update.
- Exhibits include the Press Release (99.1) and Post-ESMO Conference Call Presentation (99.2).
MacroGenics, Inc. announced its financial and operating results for the quarter ended June 30, 2024. The filing serves as a formal announcement of quarterly earnings via an attached press release.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024
- Announcement date: August 6, 2024
- The company released financial and operating results as per Item 2.02.
MacroGenics, Inc. issued an 8-K to announce the release of clinical trial data from its Phase 2 TAMARACK study evaluating vobramitamab duocarmazine for metastatic castration-resistant prostate cancer.
📋 Key Facts
- The filing relates to a press release regarding the Phase 2 TAMARACK clinical trial.
- The drug under investigation is vobramitamab duocarmazine.
- The target indication is metastatic castration-resistant prostate cancer (mCRPC).
- Filing date: July 30, 2024.
MacroGenics, Inc. entered into a Fourth Amendment to its Global Collaboration and License Agreement with Incyte Corporation. The amendment confirms the achievement of certain development milestones, triggering a $100 million payment to MacroGenics.
📋 Key Facts
- Entered into a Fourth Amendment to the existing Global Collaboration and License Agreement on July 24, 2024.
- The agreement is with Incyte Corporation.
- Certain development milestones have been deemed achieved under the terms of the amendment.
- The milestone achievement results in a $100 million payment to MacroGenics, Inc.
MacroGenics, Inc. held its 2024 Annual Meeting of Stockholders on May 21, 2024. All four proposals presented to shareholders, including director elections and auditor ratification, were approved.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Annual Meeting held on May 21, 2024.
- Quorum represented approximately 89% of the 62,560,502 shares outstanding as of March 22, 2024.
- Three Class II directors (Scott Jackson, Margaret A. Liu, M.D., and David Stump, M.D.) were elected to three-year terms.
- Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2024 was approved.
- Advisory vote on executive officer compensation (Say-on-Pay) was approved.
- Amendment to the 2023 Equity Incentive Plan to increase available shares by 2,000,000 was approved.
MacroGenics, Inc. announced its financial and operating results for the first quarter ended March 31, 2024.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024.
- Announcement date: May 9, 2024.
- The filing serves to provide the quarterly earnings press release as Exhibit 99.1.
MacroGenics, Inc. filed an 8-K to announce the posting of a new corporate presentation on its website.
📋 Key Facts
- The company posted a corporate presentation on its website on May 9, 2024.
- The presentation is included as Exhibit 99.1 in the filing.
MacroGenics, Inc. issued an 8-K to announce the release of early interim safety data from its Phase 2 TAMARACK study and outlined plans for future disclosures.
📋 Key Facts
- The filing relates to a press release regarding the Phase 2 TAMARACK Study.
- The announcement specifically concerns 'early interim safety data'.
- The company intends to provide further disclosures in the future.
MacroGenics, Inc. announced its financial and operating results for the fiscal year ended December 31, 2023. The filing serves as a formal announcement of the company's annual performance metrics.
📋 Key Facts
- Announcement date: March 7, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes the release of full financial and operating results via Exhibit 99.1.